Soleno Therapeutics, Inc. (NASDAQ:SLNO) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Shares of Soleno Therapeutics, Inc. (NASDAQ:SLNO) have earned a consensus rating of “Moderate Buy” from the fourteen analysts that are covering the company, MarketBeat.com reports. One analyst has rated the stock with a sell rating, twelve have issued a buy rating and one has assigned a strong buy rating to the company. The average 12 month target price among brokers that have issued a report on the stock in the last year is $114.50.

SLNO has been the subject of several research reports. Wall Street Zen upgraded shares of Soleno Therapeutics from a “hold” rating to a “buy” rating in a research note on Saturday, November 8th. Weiss Ratings restated a “sell (d-)” rating on shares of Soleno Therapeutics in a research report on Wednesday, October 8th. Oppenheimer raised their target price on Soleno Therapeutics from $105.00 to $110.00 and gave the company an “outperform” rating in a research report on Thursday, August 7th. HC Wainwright reissued a “buy” rating and issued a $110.00 price target (up previously from $100.00) on shares of Soleno Therapeutics in a research note on Monday, August 18th. Finally, Wells Fargo & Company reiterated an “overweight” rating and set a $106.00 price objective (down from $123.00) on shares of Soleno Therapeutics in a research note on Wednesday, November 5th.

Soleno Therapeutics Trading Down 4.4%

NASDAQ:SLNO opened at $47.25 on Tuesday. The company has a quick ratio of 15.01, a current ratio of 15.13 and a debt-to-equity ratio of 0.21. The stock has a market capitalization of $2.54 billion, a price-to-earnings ratio of -11.41 and a beta of -2.92. Soleno Therapeutics has a 52 week low of $41.50 and a 52 week high of $90.32. The firm has a 50 day moving average of $59.77 and a 200 day moving average of $71.81.

Soleno Therapeutics (NASDAQ:SLNO) last announced its earnings results on Tuesday, November 4th. The company reported $0.47 earnings per share for the quarter, topping the consensus estimate of $0.08 by $0.39. The business had revenue of $66.02 million for the quarter, compared to analysts’ expectations of $47.46 million. As a group, sell-side analysts anticipate that Soleno Therapeutics will post -3.72 earnings per share for the current fiscal year.

Institutional Trading of Soleno Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of SLNO. PharVision Advisers LLC acquired a new stake in Soleno Therapeutics during the third quarter worth about $288,000. Samlyn Capital LLC raised its holdings in shares of Soleno Therapeutics by 94.1% in the 3rd quarter. Samlyn Capital LLC now owns 466,175 shares of the company’s stock valued at $31,513,000 after buying an additional 226,048 shares during the period. Polar Capital Holdings Plc increased its stake in Soleno Therapeutics by 45.7% during the third quarter. Polar Capital Holdings Plc now owns 1,191,123 shares of the company’s stock worth $80,520,000 after purchasing an additional 373,623 shares during the period. Quarry LP purchased a new stake in Soleno Therapeutics during the 3rd quarter worth approximately $47,000. Finally, Prelude Capital Management LLC raised its stake in shares of Soleno Therapeutics by 17.9% in the third quarter. Prelude Capital Management LLC now owns 16,393 shares of the company’s stock valued at $1,108,000 after acquiring an additional 2,484 shares in the last quarter. 97.42% of the stock is owned by institutional investors and hedge funds.

Soleno Therapeutics Company Profile

Soleno Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet, which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome.